The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation represents a well-established molecular biomarker for prognosis and a predictive marker of response to alkylating therapy in IDH-wildtype glioblastoma. Here, IDH2 is linked to glioblastoma.